FDA
-
-
-
-
-
-
-
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
-
-
-
-
-
-
Horizon Therapeutics (HZNP) Reports Publication of UPLIZNA Data
-
-
-
-
-
-
-
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease
-
-
-
-
-
-
-
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Pri
-
-
-
-
-
-
-
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
-
-
-
-
-
-
-
Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
-
-
-
-
-
-
-
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
-
322,195 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

